Medicines Development for Global Health

A global health company, established to put new and improved medicines into the hands of people who will benefit from them. Newsletter:

[Medicines Development for Global Health @MedicinesDev]

@AmbGlobalHealth @apcove @MenziesResearch The support is critical to developing and providing better tools to address #NTDs at home, in our region, and across the globe. With our partners at @KirbyInstitute, @MCRI_for_kids, @telethonkids and many others around the world, we are grateful.

[Australia's Ambassador for Global Health @AmbGlobalHealth]

Australia’s building new partnerships to strengthen our shared regional #healthsecurity. With @APCOVE, @MenziesResearch & @MedicinesDev, we’re supporting countries to strengthen #OneHealth monitoring, prevent outbreaks, and develop new treatments for neglected tropical diseases.

[Medicines Development for Global Health @MedicinesDev]

@MectizanMDP @Sightsavers MDGH congratulates @MectizanMDP upon reaching this impressive milestone, not just counting the years of dedication, but the countless lives impacted. You have long been our inspiration #endNTDs

[Medicines Development for Global Health @MedicinesDev]

Medicines Development for Global Health congratulates Founder and Managing Director Mark Sullivan on being named to the 2022 PharmaVoice 100 list of top industry leaders. Read more: https://t.co/DsPKQqR9tH

[Medicines Development for Global Health @MedicinesDev]

@MedicinesDev acknowledges the Australian NGO Cooperation Program and @FredHollows for their assistance to #Vanuatu in the successful efforts to eliminate trachoma as a public health problem. https://t.co/PoyohICfYQ

[Medicines Development for Global Health @MedicinesDev]

Vanuatu validated by @WHO for eliminating trachoma as public health problem. It's the 1st country in Pacific Islands, the 4th @WHOWPRO country and 14th country globally to achieve this milestone. Congrats to all on this great success. #Vanuatu! #beatNTDs #NTDRoadmap2030

[End COVID For All @EndCOVIDForAll]

Leading 🇦🇺 voices have written to @ScottMorrisonMP calling for:

🌏$250m to COVAX to tackle global vaccine inequity

👩‍⚕️$50m to address hesitancy in our region

🦠$100m to CEPI to reduce future pandemics

Open Letter - https://t.co/FgSkYMrfRB

#EndCOVIDforAll #auspol

[Medicines Development for Global Health @MedicinesDev]

MDGH is proud to be a partner for #WorldNTDDay – Sunday January 30, 2022. Visit our website to learn more about our mission to develop new medicines for several of these important NTDs. https://t.co/SrqftfEYMF

[Medicines Development for Global Health @MedicinesDev]

Mark Sullivan, Founder of MDGH has been awarded Officer of the Order of Australia (AO), one of highest civilian honours in Australia. Mark was recognised “for distinguished service to medical research, to business, and to education”
Read more: https://t.co/mJ6rRWj8y1

[Medicines Development for Global Health @MedicinesDev]

Join MDGH at #TropMed21 virtual meeting this week, delivering 2 presentations at symposium on clin development of new treatments to eliminate onchocerciasis, and early results from open label study to find optimal dose of moxidectin in children aged 4-11. https://t.co/lLT8TajLbc

[Medicines Development for Global Health @MedicinesDev]

Our Q2 2021 Newsletter is live! Read here: https://t.co/oyQVvlTSfE

[Medicines Development for Global Health @MedicinesDev]

MDGH is pleased to announce treatment of first enrollees in 3 key clinical trials of #moxidectin in #onchocerciasis co-funded by @EDCTP: repeat dose implementation study; single-dose implementation safety study; pediatric dose-finding study #endNTDs. https://t.co/e1OBv0OOtc

[Medicines Development for Global Health @MedicinesDev]

Our annual report is now published. Find out more about our accomplishments from 2020 and our development plans for #moxidectin and CC-11050. Much work remains to be done to #endNTDs and #endTB.
Download here: https://t.co/cIIFkc7vvG

[Medicines Development for Global Health @MedicinesDev]

Results from a dose-ranging Phase 2a study of #moxidectin in #Strongyloides stercoralis infection in adults recently published in Lancet Infectious Diseases. #endNTDs https://t.co/eTf1fmqVEd

[The Lancet Infectious Diseases @TheLancetInfDis]

Plus linked Comment: Moxidectin: an ally to ivermectin for treating Strongyloides stercoralis? https://t.co/yvyA4E8Kiz

[Medicines Development for Global Health @MedicinesDev]

#TB is a major cause of ill health and one of the top 10 causes of death worldwide: 2B people have latent infection and, in 2019 alone, 1.4M died. TB is a pandemic that has been with us for thousands of years and we're still fighting it. #endTB  #WorldTBDay #theclockisticking

[Medicines Development for Global Health @MedicinesDev]

Data on our new compound #CC11050 (also known as #AMG634) on #TB published by @Auruminstitute in @TheLancet (https://t.co/VoruWUGnYA) showing positive impact on FEV1.

[Medicines Development for Global Health @MedicinesDev]

Our latest newsletter is now available. Read more about latest news from MDGH: https://t.co/WWcje8HM7X

[devpolicy.org @devpolicy]

“[W]e urge the world to look at how we’ve responded to #COVID19 and imagine – and fight for – a world where all disease threats are treated with urgency commensurate with the devastation that they wreak.” – Willo Brock, Andrea Lucard and Mark Sullivan
https://t.co/rMCq7m1a85

[Medicines Development for Global Health @MedicinesDev]

We’re proud to acknowledge the 6th UN International Day of Women and Girls in Science: 78% of our team at @MDGH are #WomeninSTEM, developing medicines and vaccines for people who need them most. We’re pleased to introduce you to some of our senior scientists: